More recently, instead of targeting tumor antigens, stimulating T cell anti-tumor immunity using bispecific T Cell Engager (BiTE) antibodies to target a tumor antigen—CD19 and the activating receptor, CD3—on T cells is the first mAb approach that enhances anti-tumor capabilities [126]. Here, CD19 is linked to neoplasm.